Good
Mostly Aligned
Patient Risk:
Low
Summary
Most claims that are mechanism/target-related are supported, while claims about FDA approval dates/firsts and year-specific approvals are not supported by the provided label sections. Overall alignment is generally sound for the included excerpts.
Category Scores
Accurate Statements
Keytruda (pembrolizumab) is a monoclonal antibody that targets the PD-1 protein on T-cells.
Supported: 12.1 Mechanism of Action (PD-1 receptor on T cells; pembrolizumab binds PD-1 as a monoclonal antibody).
Keytruda became the first PD-1 inhibitor to receive FDA approval.
Evaluation limited to provided label excerpts; claim not supported in provided sections.
In 2015, the FDA approved Keytruda for the treatment of patients with advanced melanoma.
Indication presence is supported by 1.1 Melanoma, but the year-specific approval timing is not supported by the provided label excerpts.
In 2016, the FDA approved Keytruda for the treatment of patients with head and neck squamous cell carcinoma.
Indication presence is supported by 1.4 Head and Neck Squamous Cell Cancer, but the year-specific approval timing is not supported by the provided label excerpts.
Unsupported Statements
By blocking the PD-1 protein, Keytruda allows the immune system to recognize and attack cancer cells.
12.1 supports blockade of PD-1 interaction with PD-L1/PD-L2 and release of PD-1 pathway-mediated inhibition, including anti-tumor immune response, but the specific phrasing that the immune system 'recognize and attack cancer cells' is not explicitly stated in the provided label text.
On September 4, 2014, the FDA granted Keytruda its first approval for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose disease progressed on or after platinum-based chemotherapy.
No approval date/first-approval timing is provided in the supplied label excerpts.
Keytruda became the first PD-1 inhibitor to receive FDA approval.
No comparative regulatory-history statement is provided in the supplied label excerpts.
In 2015, the FDA approved Keytruda for the treatment of patients with advanced melanoma.
While melanoma indications are present (1.1), the year '2015' and approval timing are not included in the supplied label excerpts.
In 2016, the FDA approved Keytruda for the treatment of patients with head and neck squamous cell carcinoma.
While HNSCC indications are present (1.4), the year '2016' and approval timing are not included in the supplied label excerpts.
Contradictions
Important Omissions
Any dosing/administration, contraindications, boxed warnings, detailed warnings/precautions, drug interactions, monitoring, administration/storages, or adverse reaction specifics.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The evaluated content is limited to mechanism statements and regulatory-history/year assertions. Provided excerpts do not include safety-critical PI elements; no direct contraindication/warning-related assertions were made in the claims list.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Several claims rely on approval timing/firsts/year-specific regulatory history that is not supported by the provided prescribing information excerpts.
Suggested Improvement
Restrict statements to information explicitly present in the supplied label sections (e.g., mechanism and the presence of indications) and remove or qualify approval-date/year/first-in-class claims unless the label excerpts include that regulatory-history content.